Unique Products


TAK-700

TAK-700 is an oral, selective, non-steroidal androgen synthesis inhibitor of the 17,20 lyase in clinical trials.


MLN-4924

MLN4924 is a novel NAE inhibitor in clinical trials.


CH-5424802

CH5424802 is a potent and selective ALK inhibitor


AZD-5363

AZD5363 is an AKT inhibitor in clinical trials.


INK-128

INK-128 is an mTORC1/C2 inhibitor in clinical trials.


JNJ-26481585

JNJ-26481585 is an HDAC inhibitor in clinical trials.


AZD-4547

AZD-4547 is a FGFR inhibitor in clinical trials.


GDC-0980

GDC-0980 is an inhibitor of PI3 Kinase and mTOR Kinase in clinical trials.


AZD-1480

AZD-1480 is a potent JAK2 inhibitor in clinical trials.


RO-5126766

RO-5126766 is a dual Raf and MEK inhibitor in clinical trials.


ASP-3026

ASP-3026 is an ALK inhibitor in clinical trials.


LY-2784544

LY2784544 is a small molecule selective mutant JAK2 kinase inhibitor.


TAK-441

TAK441 is a Hedgehog inhibitor.


ARRY-380

ARRY-380 is an orally active, reversible and selective ErbB-2 inhibitor


GDC-0973

GDC-0973 is an MEK inhibitor.


SB-939

SB-939 is a novel histone deacetylase (HDAC) inhibitor


XL-184

XL-184 is a c-Met inhibitor clinical trials.


LCL-161

Promoting cancer cell death by deactivating inhibitor of apoptosis proteins (IAPs).


Tubastatin A

Tubastatin A is a potent and selective HDAC6 (histone deacetylase 6) inhibitor.


ARQ-197

ARQ-197 is an orally available, small molecule inhibitor of the c-Met receptor tyrosine kinase.


SGI-1776

SGI-1776 is a PIM kinase inhibitor in clinical trials.


PR-171(Carfilzomib)

PR-171 is a Proteasome inhibitor in clinical trials.


PLX-4032

PLX-4032 is a B-Raf inhibitor in clinical trials.


PLX-4720

PLX-4720 is a B-Raf inhibitor in clinical trials.


TG-101348

TG-101348 is a JAK2 inhibitor in clinical trials.


INCB-018424

INCB-018424 is a JAK1/2 inhibitor in clinical trials.


PF-04554878

PF-04554878 is a FAK inhibitor in clinical trials.


PF-03758309

PF-03758309 is a PAK4 inhibitor in clinical trials.


CAL-101

CAL-101 is an Oral Delta Isoform-Selective PI3 Kinase Inhibitor.


BKM-120

BKM-120 is a PI3K inhibitor in clinical trials.


YM-155

YM-155 is a novel small molecule survivin inhibitor in clinical trials.


EMD-1214063

EMD-1214063 is a c-Met inhibitor in clinical trials.


PF-04691502

PF-04691502 is a potent and selective dual PI3K/mTOR inhibitor in clinical trials.


AZD-8055

AZD-8055 is an mTORC1/C2 inhibitor in clinical trials


GSK-1120212

GSK-1120212 is a MEK inhibitor in clinical trials.


OSI-906

OSI-906 is a potent, selective orally active inhibitor of the insulin-like growth factor-1 receptor (IGF-1R),and in clinical trials.


PKI-587(PF-05212384)

PKI-587(PF-05212384) is a potent and selective dual PI3K/mTOR inhibitor in clinical trials.


OSI-027

OSI-027 is an orally bioavailable mTORC1/C2 kinase inhibitor with anti-tumor activity,and in clinical trials.


ABT-263

ABT-263 is a Bcl-2 family inhibitor, orally bioavailable and in clinical trials


ABT-737

ABT-737 is a Bcl-2 family inhibitor in clinical trials.


XL-147

XL-147 is a selective PI3K inhibitor in clinical trials.


BMS-754807

BMS-754807 is an IGF-1R inhibitor in clinical trials


PF-04217903

PF-04217903 is a c-MET inhbitor in clinical trials.


MK-2206

MK-2206 is an oral potent allosteric Akt inhibitor in clinical trials


NVP-TAE-684

NVP-TAE-684 is a selective ALK inhibitor in clinical trials.


RDEA-119 (BAY-869766)

RDEA-119 (BAY-869766) is a potent and highly selective MEK inhibitor in clinical trials


AZD-6244

AZD-6244 is a novel inhibitor of MEK1/2 kinases in clinical trials


ABT-888

ABT-888 is a potent inhibitor of PARP-1 and PARP-2 (potency =5nM in vitro),and in clinical trials

Discover More

Creating places that enhance the human experience.


We always put people and nature at the center of our projects.
12
Useful options
45
Beautiful snippets
8
Amazing pages

Building Inhibitors of Signal Transduction Pathways


For pdf of product catalogue click download


ABT-263(Navitoclax)RequestCatalog# A-1001   

        ABT-263 is a Bcl-2 family inhibitor, in clinical trials

ABT-737RequestCatalog# A-1002   

        ABT-737 is a Bcl-2 family inhibitor, pre-clinical

ABT-888RequestCatalog# A-1003   

        ABT-888 is a potent inhibitor of PARP-1 and PARP-2 (potency =5nM in vitro)

AEE-788RequestCatalog# A-1105   

        AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor

AG-013736 (Axitinib)RequestCatalog# A-1156   

        Axitinib (also known as AG-013736) is a small molecule tyrosine kinase inhibitor. It inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, and cKIT (CD117).

AP-23573RequestCatalog# A-1004   

        AP-23573 (MK-8669, Deforolimus) is an mTOR inhibitor

AP-24534 (Ponatinib)RequestCatalog# A-1158   

        AP-24534 (Ponatinib), a novel inhibitor of BCR/ABL, FGFR, VEGFR.

AP-26113RequestCatalog# A-1157   

        AP-26113 is a novel potent ALK inhibitor.

AP-26113RequestCatalog# A-1157   

        AP-26113 is a novel orally available, and potent dual kinase inhibitor of ALK and EGFR.

ARQ-197(Tivantinib)RequestCatalog# A-1109   

        ARQ 197 is an orally available, small molecule inhibitor of the c-Met receptor tyrosine kinase

ARRY-380RequestCatalog# A-1177   

        ARRY-380 is an orally active, reversible and selective ErbB-2 inhibitor

AS-703026RequestCatalog# A-1005   

        AS-703026 is an MEK inhibitor.

ASA-404RequestCatalog# A-1142   

        ASA404 (5,6-dimethylxanthenone-4-acetic acid or DMXAA) is a small-molecule tumour-vascular disrupting agent (Tumour-VDA)

ASP-3026RequestCatalog# A-1171   

        ASP-3026 is an ALK inhibitor.

AT-406RequestCatalog# A-1207   

        AT-406 is an orally-active XIAP inhibitor.

AV-951(Tivozanib)RequestCatalog# A-1118   

        AV-951 is a potent and selective inhibitor of VEGFR-1, 2 & 3 kinases.

AZD-0530RequestCatalog# A-1006   

        

AZD-1480RequestCatalog# A-1135   

        AZD-1480 is a potent JAK2 inhibitor (IC50 = 260 pM)

AZD-2014RequestCatalog# A-1090   

        AZD-2014 is a mTOR inhibitor in clinical trials

AZD-2281 (Olaparib)RequestCatalog# A-1125   

        Highly potent, oral and selective inhibitor of poly(ADP-ribose) polymerase (PARP)

AZD-4547RequestCatalog# A-1174   

        AZD-4547 is a FGFR inhibitor.

AZD-5363RequestCatalog# A-1183   

        AZD5363 is an AKT inhibitor.

AZD-6244(ARRY-142886, Selumetinib)RequestCatalog# A-1007   

        AZD-6244 is a novel inhibitor of MEK1/2 kinases,effectively inhibited the proliferation of acute biphenotypic leukemia MV4-11 and acute monocytic leukemia MOLM13 cells

AZD-7762RequestCatalog# A-1116   

        AZD-7762 is a checkpoint kinase inhibitor in clinical trials.

AZD-8055RequestCatalog# A-1008   

        AZD-8055 is an mTORC1/C2 inhibitor with an IC50 of 0.8 nmol/L, in clinical trials

AZD-8931RequestCatalog# A-1197   

        AZD8931 is a potent, reversible, small-molecule inhibitor against ErbB1 , ErbB2 and ErbB3 kinases.

b-AP15RequestCatalog# A-1194   

        b-AP15 is a novel inhibitor of proteasome activity, with a different mechanism of action than the available and widely used proteasome inhibitors such as bortezomib.

BAY-869766 (RDEA-119)RequestCatalog# A-1036   

        BAY-869766 (RDEA-119) is a potent and highly selective MEK Inhibitor

BAY73-4506 (Regorafenib)RequestCatalog# A-1112   

        Regorafenib (BAY73-4506) is an oral multikinase inhibitor, including B-Raf (IC50, 69 nM), c-KIT (IC 50, 17 nM), VEGFR2 (IC50, 40nM)

BAY87-2243RequestCatalog# A-1178   

        

BEZ-235RequestCatalog# A-1009   

        BEZ-235 is a PI3K/mTOR inhibitor in clinical trials

BGJ-398RequestCatalog# A-1143   

        NVP-BGJ398 is an FGFR kinase inhibitor

BGT-226RequestCatalog# A-1070   

        BGT-226 is a PI3K/mTOR inhibitor in clinical trials

BI-2536RequestCatalog# A-1010   

        BI-2536 is a potent inhibitor of the mitotic kinase plk1. It causes mitotic arrest and induces apoptosis in human cell lines of various origin and has progressed into clinical trials (1,2).

BI-6727RequestCatalog# A-1187   

        BI6727 is a dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity.

BIBW-2992 (Tovok)RequestCatalog# A-1122   

        BIBW-2992 (Tovok) is an irreversible, potent, orally bioavailable inhibitor of EGFR and HER2 ...

BKM-120RequestCatalog# A-1108   

        BKM-120 is a PI3K inhibitor in clinical trials.

BMS-536924RequestCatalog# A-1011   

        BMS-536924 is an inhibitor of the IGF-IR (IC50 = 100 nM), InsR and fokal adhesion kinase

BMS-599626RequestCatalog# A-1012   

        BMS-599626 is a pan-HER Kinase Inhibitor

BMS-754807RequestCatalog# A-1013   

        BMS-754807 is an IGF-1R inhibitor, in phase I clinical trials

BMS-777607RequestCatalog# A-1155   

        BMS-777607 is a Small-Molecule Met Kinase Inhibitor.

BMS-863233(XL-413)RequestCatalog# A-1072   

        BMS-863233 (XL-413) is a CDC7 inhibitor in clinical trials.

BMS-911543RequestCatalog# A-1175   

        BMS-911543 is a JAK2 Inhibitor.

Bortezomib (PS-341)RequestCatalog# A-1014   

        Bortezomib (PS-341) is a proteasome inhibitor

Brivanib(BMS-582664)RequestCatalog# A-1160   

        Brivanib(BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.

BYL-719RequestCatalog# A-1214   

        BYL719 is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.

CAL-101RequestCatalog# A-1138   

        CAL-101 is an Oral Delta Isoform-Selective PI3 Kinase Inhibitor.

Cediranib(AZD-2171)RequestCatalog# A-1161   

        Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.

CEP-18770RequestCatalog# A-1095   

        CEP-18770 is a Proteasome inhibitor in clinical trials

CEP-9722RequestCatalog# A-1188   

        CEP-9722 is a PARP inhibitor.

CH-5132799RequestCatalog# A-1215   

        CH5132799, a novel class I PI3K inhibitor, exhibited a strong inhibitory activity especially against PI3K汐 (IC(50)=0.014 米M).

CH-5424802RequestCatalog# A-1176   

        CH5424802 is a potent and selective ALK inhibitor

CHR-3996RequestCatalog# A-1082   

        CHR-3996 is a HDAC inhibitor in clinical trials

CI-1033RequestCatalog# A-1015   

        CI-1033is an inhibitor of EGFR , HER-2 and ErbB-4

CI-1040(PD 184352)RequestCatalog# A-1064   

        ATP-noncompetitive MEK inhibitor

CyclopamineRequestCatalog# A-1057   

        Cyclopamine is a hegehog pathway inhibitor.

EMD-1214063RequestCatalog# A-1087   

        EMD-1214063 is a c-Met inhibitor in clinical trials

GDC-0068RequestCatalog# A-1205   

        GDC-0068 is a highly selective ATP-competitive pan-Akt inhibitor that inhibits all three isoforms of Akt with IC50 values of 5 to 30 nM.

GDC-0449RequestCatalog# A-1113   

        GDC-0449 is an orally-administered small molecule antagonist of Hedgehog signaling pathway.

GDC-0623RequestCatalog# A-1181   

        GDC-0623 is an MEK inhibitor.

GDC-0941RequestCatalog# A-1017   

        GDC-0941 is a PI3K inhibitor

GDC-0973 (XL-518)RequestCatalog# A-1180   

        GDC-0973(XL-518) is an MEK inhibitor.

GDC-0980RequestCatalog# A-1069   

        GDC-0980 is a PI3K/mTOR inhibitor in clinical trials

Gleevec (STI-571)RequestCatalog# A-1018   

        Imatinib Methanesulfonate, STI-571, CGP-57148B, Glivec,

GSK-1120212(JTP-74057)RequestCatalog# A-1083   

        GSK-1120212 is a MEK inhibitor in clinical trials

GSK-1363089 (XL-880)RequestCatalog# A-1086   

        GSK-1363089 (XL-880) is a c-Met inhibitor in clinical trials

GSK-2126458RequestCatalog# A-1067   

        GSK-2126458 is a PI3K/mTOR inhibitor in clinical trials

GSK-2141795RequestCatalog# A-1019   

        

GSK-2256098RequestCatalog# A-1078   

        GSK-2256098 is a FAK inhibitor in clinical trials

GSK-690693RequestCatalog# A-1020   

        GSK-690693 is an inhibit of Akt kinases 1, 2, and 3

GW-572016RequestCatalog# A-1021   

        GW-572016 is an inhibitor of EGFR(Ki=3nM),ErbB-2(Ki=13nM),ErbB-4(Ki=347nM)

HSP-990RequestCatalog# A-1144   

        HSP990 is an orally available Hsp90 inhibitor

INC-280RequestCatalog# A-1145   

        Oral, highly selective c-Met receptor tyrosine kinase (RTK) inhibitor

INC-424RequestCatalog# A-1146   

        An oral, Janus kinase (JAK) inhibitor selective for JAK1 and JAK2

INCB-018424RequestCatalog# A-1134   

        INCB018424 is an oral, selective JAK inhibitor

INK-1117RequestCatalog# A-1132   

        INK-1117 is an orally-available PI3K汐-isoform inhibitor.

INK-1197RequestCatalog# A-1133   

        INK-1197 is an orally available dual delta/gamma-specific inhibitor of PI3K.

INK-128RequestCatalog# A-1023   

        INK-128 is an mTORC1/C2 inhibitor

IPI-269609RequestCatalog# A-1063   

        An orally bioavailable small-molecule inhibitor of Hedgehog

IPI-926RequestCatalog# A-1062   

        IPI-926 is a novel, potent, orally-available small molecule inhibitor of the Hedgehog pathway.

Iressa (Gefitinib)RequestCatalog# A-1024   

        Iressa is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which was approved for cancer treatment by FDA.

ITF-2357RequestCatalog# A-1186   

        ITF2357 is a noverl HDAC inhibitor.

JNJ-26481585RequestCatalog# A-1162   

        JNJ-26481585 is an orally bioavailable, second-generation, hydroxamic acid-based inhibitor of HDAC with potential antineoplastic activity.

JNJ-38877605RequestCatalog# A-1119   

        JNJ-38877605 is an orally available selective c-Met inhibitor in clinical.

KRP-203RequestCatalog# A-1213   

        KRP-203 is an EDG3 inhibitor in clinical trials.

KU-0063794RequestCatalog# A-1124   

        Selective inhibitor of mammalian target of rapamycin (mTOR)

KW-2478RequestCatalog# A-1115   

        KW-2478 is an Hsp90 inhibitor in clinical trials.

LBH-589RequestCatalog# A-1025   

        LBH-589 is a highly potent deacetylase inhibitor shown to impede multiple pathways implicated in cancer associated with cutaneous T-cell lymphoma and other challenging malignancies.

LCL-161RequestCatalog# A-1147   

        Promoting cancer cell death by deactivating inhibitor of apoptosis proteins (IAPs)

LDK-378RequestCatalog# A-1189   

        LDK-378 is an ALK inhibitor.

LY-2784544RequestCatalog# A-1170   

        LY2784544 is a small molecule selective mutant JAK2 kinase inhibitor.

LY-2874455RequestCatalog# A-1198   

        LY2874455 is a Novel FGF/FGFR Inhibitor.

LY2801653RequestCatalog# A-1182   

        LY2801653 is a c-Met inhibitor.

MEK-162 (ARRY-162)RequestCatalog# A-1128   

        MEK-162(ARRY-162) is an MEK inhibitor in clinical trials

MGCD-0103 (Mocetinostat)RequestCatalog# A-1106   

        MGCD-0103 (Mocetinostat) is HDAC inhibitor, and inhibits Class 1 isoforms of HDAC,specifically HDAC 1(IC50=0.15umol/l), 2(IC50=0.29umol/l) and3(IC50=1.66umol/l).

MIDOSTAURIN(PKC412)RequestCatalog# A-1148   

        PKC412 (midostaurin) is an oral multi-targeted kinase inhibitor

MK-1775RequestCatalog# A-1117   

        MK-1775 is a potent and selective Wee1 kinase inhibitor in vitro and in vivo.

MK-2206RequestCatalog# A-1026   

        MK-2206 is an oral potent allosteric Akt inhibitor (IC50=8nM,2nM,65nM for Akt1 Akt2 and Akt3 resp.)

MK-470RequestCatalog# A-1199   

        MK-470 is an SYK inhibitor.

MK-4827RequestCatalog# A-1092   

        MK-4827 is a PARP inhibitor in clinical trials

MK-8033RequestCatalog# A-1107   

        MK-8033 is a c-MET inhibitor in clinical trials

MK-8669 (AP-23573, Deforolimus)RequestCatalog# A-1004   

        MK-8669 (AP-23573, Deforolimus) is an mTOR inhibitor.

MLN-2480RequestCatalog# A-1192   

        MLN -2480 is a pan Raf inhibitor in chinical trials.

MLN-4924RequestCatalog# A-1139   

        MLN4924 is a novel NAE inhibitor, on blood and skin.

MLN-8237RequestCatalog# A-1123   

        MLN8237 is a second-generation, selective AAK inhibitor.

MLN-9708RequestCatalog# A-1097   

        MLN-9708 is a Proteasome inhibitor in clinical trials

MS-275RequestCatalog# A-1059   

        MS-275 is a histone deacetylase inhibitor.

NBI-0052RequestCatalog# A-1096   

        NBI-0052 is a Proteasome inhibitor in clinical trials

NMS-1116354RequestCatalog# A-1073   

        NMS-1116354 is a CDC7 inhibitor in clinical trials.

NMS-1286937RequestCatalog# A-1094   

        NMS-1286937 is a PLK inhibitor in clinical trials

NPI-0052RequestCatalog# A-1141   

        NPI-0052 is a novel proteasome inhibitor.

NV-128RequestCatalog# A-1027   

        NV-128 is an mTOR inhibitor

NVP-AUY-922RequestCatalog# A-1111   

        NVP-AUY922 is a novel Hsp90 inhibitor

NVP-LDE-225 (free base)RequestCatalog# A-1126   

        NVP-LDE-225 is an Hedgehog inhibitor in clinical trials

NVP-TAE-684RequestCatalog# A-1046   

        NVP-TAE-684 is a selective NPM-ALK inhibitor with IC50 values between 2 and 10 nM. Treatment of TAE684 resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest in cancer cells.

Obatoclax (GX15-070)RequestCatalog# A-1022   

        Obatoclax (GX15-070) is an inhibit of the Bcl-2.

OPB-31121RequestCatalog# A-1104   

        OPB-31121 is a Stat3 in clinical trials

OSI-027RequestCatalog# A-1065   

        OSI-027 is an orally bioavailable mTORC1/C2 kinase inhibitor with anti-tumor activity.

OSI-906RequestCatalog# A-1058   

        OSI-906 is a potent, selective orally active inhibitor of the insulin-like growth factor-1 receptor (IGF-1R).

OSU-03012RequestCatalog# A-1209   

        OSU-03012 is a PDK1 inhibitor in clinical trials.

P-1446A-05RequestCatalog# A-1074   

        P-1446A-05 is a CDK inhibitor in clinical trials.

P-276-00RequestCatalog# A-1076   

        P-276-00 is a CDK inhibitor in clinical trials

PCI-24781RequestCatalog# A-1081   

        PCI-24781 is a HDAC inhibitor in clinical trials

PCI-32765RequestCatalog# A-1201   

        PCI-32765 is a BTK inhibitor in clinical trials.

PD-0332991RequestCatalog# A-1030   

        PD-0332991 is an orally available Cdk inhibitor.

PF-00562271RequestCatalog# A-1080   

        PF-00562271 is a FAK inhibitor in clinical trials

PF-01367338RequestCatalog# A-1093   

        PF-01367338 is a PARP inhibitor in clinical trials

PF-02341066RequestCatalog# A-1031   

        PF-02341066 is a potent and selective dual ALK and c-MET inhibitor in clinical trials.

PF-03758309RequestCatalog# A-1091   

        PF-03758309 is a PAK4 inhibitor in clinical trials

PF-04217903RequestCatalog# A-1114   

        PF-04217903 is a c-MET inhbitor

PF-04554878RequestCatalog# A-1079   

        PF-04554878 is a FAK inhibitor in clinical trials

PF-04691502RequestCatalog# A-1101   

        PF-04691502 is a potent and selective dual PI3K/mTOR inhibitor in clinical trials.

PF-05212384 (PKI-587)RequestCatalog# A-1071   

        PF-05212384 (PKI-587) is a potent and selective dual PI3K/mTOR inhibitor in clinical trials.

PF4989216RequestCatalog# A-1184   

        

PHA-665752RequestCatalog# A-1032   

        PHA-665752 is a potent, selective and ATP-competitive inhibitor of c-MET kinase

PHA-848125ACRequestCatalog# A-1204   

        PHA-848125AC is an orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity.

PKI-587(PF-05212384)RequestCatalog# A-1071   

        PF-05212384 (PKI-587) is a potent and selective dual PI3K/mTOR inhibitor in clinical trials.

PLX-4032(RG7204, RO5185426, Vemurafenib)RequestCatalog# A-1130   

        PLX-4032 is a B-Raf inhibitor

PLX-4720RequestCatalog# A-1131   

        PLX-4720 is a B-Raf inhibitor.

PLX108-01RequestCatalog# A-1203   

        PLX108-01 (PLX3397) is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.

Pp-242RequestCatalog# A-1033   

        Pp-242 is an mTORC1/C2 inhibitor

PR-171(Carfilzomib)RequestCatalog# A-1098   

        PR-171 is a Proteasome inhibitor in clinical trials

PTC-124RequestCatalog# A-1034   

        

PX-866RequestCatalog#    

         PX-866 is a PI3K inhibitor in clinical trials

R-935788RequestCatalog# A-1200   

        R-935788 is an SYK inhibitor.

RAF-265RequestCatalog# A-1149   

        An oral, highly selective RAF and VEGFR kinase inhibitor

Rapamycin (Sirolimus)RequestCatalog# A-1035   

        Rapamycin is a mammalian target of rapamycin (mTOR C1) inhibitor

RDEA-119 (BAY-869766)RequestCatalog# A-1036   

        RDEA-119 (BAY-869766) is a potent and highly selective MEK Inhibitor

RDEA-427RequestCatalog# A-1037   

        

RDEA-436RequestCatalog# A-1038   

        RDEA-436 is a novel, potent, broadly active MEK inhibitor, with a low EC50 in human serum

RDEA-594RequestCatalog# A-1039   

        

RDEA-806RequestCatalog# A-1040   

        

Regorafenib (BAY73-4506)RequestCatalog# A-1112   

        Regorafenib (BAY73-4506) is an oral multikinase inhibitor, including B-Raf (IC50, 69 nM), c-KIT (IC 50, 17 nM), VEGFR2 (IC50, 40nM)

ResminostatRequestCatalog# A-1190   

        Resminostat is an HDAC inhibitor in clinicals.

RO-4987655RequestCatalog# A-1084   

        RO-4987655 is a MEK inhibitor in clinical trials

RO-5126766RequestCatalog# A-1085   

        RO-5126766 is a dual Raf and MEK inhibitor in clinical trials.

RO-5185426/PLX-4032RequestCatalog# A-1150   

        RO5185426 (also known as PLX4032) is a B-RAF inhibitor.

RO-5212054/PLX-3603RequestCatalog# A-1151   

        RO-5212054/PLX-3603 is a B-Raf inhibitor.

RO-5323441RequestCatalog# A-1152   

        RO-5323441

SAHA (Vorinostat)RequestCatalog# A-1041   

        SAHA is an HDAC inhibitor and shows IC 50 of 10 nM (HDAC-1) and 300 nM (rat liver HDAC)

SB-1518RequestCatalog# A-1136   

        SB-1518 is a JAK2 inhibitor.

SB-216763RequestCatalog# A-1042   

        

SB-431542RequestCatalog# A-1043   

        SB-431542 is a potent and selective inhibitor of transforming growth factor superfamily type I activin receptor-like kinase (ALK) receptors.

SB-939RequestCatalog# A-1185   

        SB-939 is a novel histone deacetylase (HDAC) inhibitor.

SCH-727965RequestCatalog# A-1075   

        SCH-727965 is a CDK inhibitor in clinical trials

SCH-900353RequestCatalog# A-1191   

        SCH-900353 is an ERK1 inhibitor.

SCH-900776RequestCatalog# A-1202   

        SCH 900776 is a potent and selective CHK1 inhibitor with IC50 of 3 nM, 0.16 and 1.5 米M for CHK1, CDK2 and CHK2, respectively.

SGI-1776RequestCatalog# A-1102   

        SGI-1776 is a PIM kinase inhibitor in clinical trials

SGX-523RequestCatalog# A-1060   

        SGX523 is an orally bioavailable Met inhibitor

SilmitasertibRequestCatalog# A-1211   

        Silmitasertib is an orally bioavailable small-molecule inhibitor of CK2 with potential antineoplastic activity.

Sorafenib (BAY 43-9006)RequestCatalog# A-1044   

        

SR-13668RequestCatalog# A-1206   

        SR13668, an orally active Akt/PKB pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies.

STA-9090RequestCatalog# A-1179   

        STA-9090 is an HSP-90 inhibitor.

SutentRequestCatalog# A-1045   

        Sunitinib (marketed as Sutent, and previously known as SU11248) is an oral RTK inhibitor that was approved by the FDA

TAK-441RequestCatalog# A-1172   

        TAK441 is a Hedgehog inhibitor.

TAK-700RequestCatalog# A-1193   

        TAK-700 is an oral, selective, non-steroidal androgen synthesis inhibitor of the 17,20 lyase in clinical trials.

TalarozoleRequestCatalog# A-1212   

        Talarozole is a Cyp26 inhibitor in clinical trials.

TamoxifenRequestCatalog# A-1047   

        Tamoxifen is an antagonist of the estrogen receptor in breast tissue.

Tarceva (Erlotinib, OSI-774)RequestCatalog# A-1048   

        Tarceva is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which was approved for cancer treatment by FDA.

TG-101348RequestCatalog# A-1140   

        TG-101348 is a potent, highly selective JAK2 inhibitor

TG-2RequestCatalog# A-1208   

        TG-2 is an ERK/Flt3/Jak2 inhibitor in clinical trials.

TGX-221RequestCatalog# A-1050   

        TGX-221 is a cell-permeable morpholino-pyrimidinone compound that acts as a reversible, ATP-competitive, selective, and highly potent inhibitor of PI 3-Kb

TKI-258(CHIR-258, Dovitinib)RequestCatalog# A-1129   

        TKI258 is a novel FGFR/PDGFR/VEGFR inhibitor

Tubastatin ARequestCatalog# A-1159   

        Tubastatin A is a potent and selective HDAC6 (histone deacetylase 6) inhibitor.

VX-11eRequestCatalog# A-1195   

        VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK2.

WYE-354RequestCatalog# A-1051   

        WYE-354 is an mTOR inhibitor

XL-019RequestCatalog# A-1137   

        XL019 is a potent JAK2 inhibitor (IC50 = 2 nM)

XL-138RequestCatalog# A-1173   

        

XL-147RequestCatalog# A-1052   

        XL-147 is a PI3k inhibitor

XL-184RequestCatalog# A-1089   

        XL-184 is a c-Met inhibitor in clinical trials

XL-518RequestCatalog# A-1180   

        XL-518 is a potent selective orally bioavailable MEK1 inhibitor.

XL-765RequestCatalog# A-1068   

        XL-765 is a PI3K/mTOR inhibitor in clinical trials;

Y-39983RequestCatalog# A-1210   

        Y-39983 is a novel Rock1 inhibitor in clinical trials.

YM-155RequestCatalog# A-1061   

        YM-155 is a novel small molecule survivin inhibitor.

ZM-447439RequestCatalog# A-1054   

        

ZSTK-474RequestCatalog# A-1055   

        ZSTK-474 is a PI3Ka/b/g/d inhibitor


*Note: These products are for research purposes only, not for human consumption.


As 436 clients before you, let’s work together